Abstract
Background:Breast cancer (BC) is a commonly reported cancer that is widely prevalent among women. Its early detection improves patient survival and results in better outcomes. For diagnosis and follow-up care, tumor markers are one of the feasible investigations to be ordered. 8-Iso-prostaglandin F2 alpha (8-iso-PGF2 alpha) serves as a serum marker reflecting oxidative stress and subsequent damaging of DNA. In the present study, we aimed to evaluate both diagnostic and predictive values of 8-iso-PGF2 alpha in BC patients.Materials and Methods:Serum levels of 8-iso-PGF2 alpha were assessed for 66 women with benign breast tumors and 65 women who had malignant BC. To compare the patients who had breast tumors with healthy individuals, 63 women free of breast diseases were selected as controls.Results:The serum level of 8-iso-PGF2 alpha in the BC patients (57.92 pg/mL) was significantly higher compared to those with benign tumors (18.89 pg/mL) (p< 0.001). In addition, individuals with no breast diseases had less 8-iso-PGF2 alpha (4.02 pg/mL) compared to those who had developed a tumor (p< 0.001). Serum 8-iso-PGF2 alpha was found to be positively correlated with both carcinoembryonic antigen (r= 0.74,p< 0.001) and cancer antigen 15-3 (r= 0.80,p< 0.001). Furthermore, serum 8-iso-PGF2 alpha showed high diagnostic performance in BC (AUC = 0.999, sensitivity = 100%, specificity = 99.2% at a cutoff value of 36.18 pg/mL).Conclusions:Our study found that the high level of serum 8-iso-PGF2 alpha helps to provide a non-invasive indicator to detect BC. Future work with a larger sample size and various phases of BC can confirm the current results which provide insights into the early detection of cancer. (c) 2020 S. Karger AG, Basel